FI4175951T3 - Hpk1-estäjiä ja niiden käyttötapoja - Google Patents

Hpk1-estäjiä ja niiden käyttötapoja Download PDF

Info

Publication number
FI4175951T3
FI4175951T3 FIEP21742686.5T FI21742686T FI4175951T3 FI 4175951 T3 FI4175951 T3 FI 4175951T3 FI 21742686 T FI21742686 T FI 21742686T FI 4175951 T3 FI4175951 T3 FI 4175951T3
Authority
FI
Finland
Prior art keywords
pharmaceutically acceptable
acceptable salt
stereoisomer
compound according
cancer
Prior art date
Application number
FIEP21742686.5T
Other languages
English (en)
Finnish (fi)
Inventor
Wenge Zhong
Xiaotian Zhu
Song Feng
Lei Wu
Wei Huang
Hao Liu
Rongqiang Liu
Kate Xin Wen
Hua Zhou
Original Assignee
Regor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74100919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI4175951(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regor Pharmaceuticals Inc filed Critical Regor Pharmaceuticals Inc
Application granted granted Critical
Publication of FI4175951T3 publication Critical patent/FI4175951T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FIEP21742686.5T 2019-07-04 2021-07-02 Hpk1-estäjiä ja niiden käyttötapoja FI4175951T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019094634 2019-07-04
PCT/CN2020/100134 WO2021000935A1 (en) 2019-07-04 2020-07-03 Hpk1 inhibitors and uses thereof
PCT/CN2021/104206 WO2022002237A1 (en) 2019-07-04 2021-07-02 Hpk1 inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
FI4175951T3 true FI4175951T3 (fi) 2024-07-10

Family

ID=74100919

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP21742686.5T FI4175951T3 (fi) 2019-07-04 2021-07-02 Hpk1-estäjiä ja niiden käyttötapoja

Country Status (16)

Country Link
US (2) US12612424B2 (cg-RX-API-DMAC7.html)
EP (2) EP3994133A4 (cg-RX-API-DMAC7.html)
JP (2) JP7633989B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220044495A (cg-RX-API-DMAC7.html)
CN (2) CN114555585B (cg-RX-API-DMAC7.html)
AU (2) AU2020298649B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022000064A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145973A1 (cg-RX-API-DMAC7.html)
DK (1) DK4175951T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981368T3 (cg-RX-API-DMAC7.html)
FI (1) FI4175951T3 (cg-RX-API-DMAC7.html)
IL (1) IL289612B2 (cg-RX-API-DMAC7.html)
MA (1) MA56462A (cg-RX-API-DMAC7.html)
MX (2) MX2022000271A (cg-RX-API-DMAC7.html)
TW (1) TWI878319B (cg-RX-API-DMAC7.html)
WO (2) WO2021000935A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
WO2021000935A1 (en) 2019-07-04 2021-01-07 Qilu Regor Therapeutics Inc. Hpk1 inhibitors and uses thereof
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
CN116456985A (zh) * 2020-09-23 2023-07-18 深圳市原力生命科学有限公司 作为hpk1调节剂的嘧啶及吡啶衍生物和其使用方法
US20230399327A1 (en) * 2020-10-28 2023-12-14 Adlai Nortye Biopharma Co., Ltd. High activity hpk1 kinase inhibitor
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117295737A (zh) * 2021-03-05 2023-12-26 林伯士萨顿公司 Hpk1拮抗剂和其用途
CN117295748A (zh) * 2021-03-08 2023-12-26 缆图药品公司 Map4k1抑制剂
JP2024510176A (ja) * 2021-03-08 2024-03-06 ブループリント メディシンズ コーポレイション Map4k1阻害剤
TW202246263A (zh) * 2021-03-23 2022-12-01 大陸商杭州阿諾生物醫藥科技有限公司 Hpk1激酶抑制劑化合物
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CN117377673A (zh) * 2021-03-29 2024-01-09 林伯士萨顿公司 Hpk1拮抗剂和其用途
TW202304906A (zh) * 2021-04-08 2023-02-01 大陸商杭州阿諾生物醫藥科技有限公司 高活性hpk1激酶抑制劑
MX2024000751A (es) * 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.
WO2023001794A1 (en) 2021-07-20 2023-01-26 Astrazeneca Ab Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
EP4377318A4 (en) * 2021-07-30 2025-06-04 BeiGene, Ltd. PYRROLO[2,3-B PYRAZINE-BASED BIFUNCTIONAL COMPOUNDS AS HPK1 DEGRADERS AND USE THEREOF
WO2023083299A1 (zh) * 2021-11-12 2023-05-19 微境生物医药科技(上海)有限公司 作为hpk1抑制剂的稠环化合物
WO2023134608A1 (zh) * 2022-01-11 2023-07-20 微境生物医药科技(上海)有限公司 作为hpk1抑制剂的稠环化合物
WO2023245329A1 (en) * 2022-06-20 2023-12-28 Biofront Ltd Multi-kinase inhibitors, compositions thereof, and methods of using the same
CN117447470B (zh) * 2023-02-20 2026-05-01 杭州医学院 一种作为hpk1抑制剂的吡咯并吡啶衍生物、制备方法及其应用
CN116813692A (zh) * 2023-06-29 2023-09-29 凌科药业(杭州)有限公司 含磷化合物、其药物组合物及其用途
WO2025096647A1 (en) * 2023-10-30 2025-05-08 Nimbus Saturn, Inc. Methods of treating tumors
WO2025137168A2 (en) 2023-12-19 2025-06-26 Regor Pharmaceuticals, Inc. Salt and solid forms of a hpk1 inhibitor
WO2025255343A1 (en) * 2024-06-06 2025-12-11 Dana-Farber Cancer Institute, Inc. Pyrrolopyrimidine inhibitors of wild-type and mutant lrrk2

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028724A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007041511A2 (en) 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
WO2008003766A2 (en) 2006-07-06 2008-01-10 Boehringer Ingelheim International Gmbh 4-heter0cycl0alkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
CA2673003A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
WO2008110508A1 (en) 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity
WO2009084695A1 (ja) * 2007-12-28 2009-07-09 Carna Biosciences Inc. 2-アミノキナゾリン誘導体
US20100121052A1 (en) 2008-06-20 2010-05-13 Rama Jain Novel compounds for treating proliferative diseases
EP2248907A1 (en) 2009-05-08 2010-11-10 Rijksuniversiteit Groningen Gluco-oligosaccharides comprising (alpha 1-->4) and (alpha 1-->6) glycosidic bonds, use thereof, and methods for providing them
WO2012135631A1 (en) * 2011-03-30 2012-10-04 Arrien Pharmaeuticals Llc Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
US9708336B2 (en) 2014-01-22 2017-07-18 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
US20170137426A1 (en) * 2014-03-28 2017-05-18 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
CN106188029B (zh) * 2015-05-05 2018-09-18 山东轩竹医药科技有限公司 二并环类间变性淋巴瘤激酶抑制剂
ES2921257T3 (es) 2016-06-20 2022-08-22 Daegu Gyeongbuk Medical Innovation Found Nuevo derivado de imidazopiridina, procedimiento para prepararlo y composición farmacéutica que contiene el mismo como ingrediente activo para prevenir o tratar el cáncer
WO2018002219A1 (en) 2016-06-30 2018-01-04 Janssen Pharmaceutica Nv Cyanoindoline derivatives as nik inhibitors
AR109596A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos pirazolopiridina y sus usos
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
US11180482B2 (en) 2016-11-30 2021-11-23 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3587422A4 (en) 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
EP3596075B1 (en) 2017-03-15 2023-10-11 F. Hoffmann-La Roche AG Azaindoles as inhibitors of hpk1
US20200071326A1 (en) 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
WO2018215668A1 (en) 2017-05-26 2018-11-29 Glenmark Pharmaceuticals S.A. Novel inhibitors of map4k1
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN109721620B (zh) 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 Hpk1抑制剂及其用途
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
WO2020235902A1 (ko) 2019-05-17 2020-11-26 주식회사 보로노이 헤테로고리 융합 피리미딘 유도체 및 이의 용도
WO2021000935A1 (en) 2019-07-04 2021-01-07 Qilu Regor Therapeutics Inc. Hpk1 inhibitors and uses thereof

Also Published As

Publication number Publication date
MX2022000271A (es) 2022-04-20
WO2022002237A1 (en) 2022-01-06
CN114555585A (zh) 2022-05-27
CA3145973A1 (en) 2021-01-07
US20230339896A1 (en) 2023-10-26
MA56462A (fr) 2022-05-11
BR112022000064A2 (pt) 2022-05-24
TW202116751A (zh) 2021-05-01
AU2021299849A1 (en) 2023-02-23
CN116096370A (zh) 2023-05-09
AU2020298649B2 (en) 2026-04-09
EP3994133A4 (en) 2023-11-22
KR20220044495A (ko) 2022-04-08
MX2023000025A (es) 2023-04-04
IL289612B2 (en) 2026-02-01
CN116096370B (zh) 2024-12-20
KR20230035061A (ko) 2023-03-10
WO2021000935A1 (en) 2021-01-07
DK4175951T3 (da) 2024-07-29
US12612424B2 (en) 2026-04-28
AU2020298649A1 (en) 2022-02-17
JP7759374B2 (ja) 2025-10-23
TWI878319B (zh) 2025-04-01
US12617811B2 (en) 2026-05-05
EP4175951B1 (en) 2024-05-01
EP3994133A1 (en) 2022-05-11
JP7633989B2 (ja) 2025-02-20
ES2981368T3 (es) 2024-10-08
IL289612B1 (en) 2025-10-01
EP4175951A1 (en) 2023-05-10
JP2022538923A (ja) 2022-09-06
US20220389037A1 (en) 2022-12-08
JP2023533938A (ja) 2023-08-07
CN114555585B (zh) 2025-02-11
IL289612A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
MX2024000780A (es) Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon.
PH12021552675A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
PH12022551574A1 (en) Egfr inhibitors
JP2017506227A5 (cg-RX-API-DMAC7.html)
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
IN2015DN02829A (cg-RX-API-DMAC7.html)
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
EA201170061A1 (ru) Новые производные фенилимидазола в качестве ингибиторов фермента pde10a
BR112014018199A8 (pt) inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
EA201892541A1 (ru) Гуманизированные анти-il-1r3 антитела
WO2019161221A3 (en) Selective bcl-2 inhibitors in combination with an anti-pd-1 or an anti-pd-l1 antibody for the treatment of cancers
EA201990374A1 (ru) Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков
MX388579B (es) Combinacion de un compuesto de cromeno y un segundo agente activo.
WO2020132560A3 (en) Compositions and methods for cancer therapy
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
MX2021010228A (es) Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel.
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
MX2022014734A (es) Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab.
WO2019217933A8 (en) Inhibitors of the ras oncoprotein, methods of making and methods of use thereof
MX2021006210A (es) Metodos para diagnosticar y/o tratar una hepatopatia, nefropatia o neumopatia aguda o cronica.